Delfi’s $225M Raise Accelerates Development of Cancer Detection Check-Up Test

Looking to finance a 15,000-person trial to accelerate market entry for a new blood test aiding early detection of lung as well as other cancers, life sciences heavyweight Delfi Diagnostics recently added $225 million to its investment purse. The Series B round, led by DFJ Growth with participation from Eli Lilly and Co...